Want to see AU:CYP full AI Analyst Report?
CYP Stock Chart & Stats
AU$0.29
-AU$0.01(-4.17%)
At close: 4:00 PM EST
AU$0.29
-AU$0.01(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.44
Previous CloseN/A
Volume63.41K
Average Volume (3M)233.82K
Market Cap
AU$2.92M
Enterprise ValueAU$60.71M
Total Cash (Recent Filing)AU$2.59M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding243,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$19.90M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt materially reduces financial risk and interest burden, preserving flexibility to fund R&D or partner deals. Over a 2–6 month horizon a debt-free capital structure supports execution of clinical programs and licensing negotiations without near-term solvency pressure.
Scalable Allogeneic Cymerus PlatformAn iPSC‑derived, off‑the‑shelf manufacturing platform is a durable competitive asset: it enables scale, multi‑indication development and attractive partnership economics. Structural platform advantages support licensing, cost decline with scale, and long‑term market opportunity.
Very High Gross Margin ProfileNear‑100% gross margins imply low incremental production cost versus realized revenue, creating high operating leverage. If recurring partners or product sales materialize, this margin profile supports rapid margin expansion and durable profitability once fixed costs are covered.
Bears Say
Sustained Negative Operating And Free Cash FlowPersistent cash outflows force reliance on external funding or dilutive capital raises, limiting strategic optionality. Over months this cash burn constrains ability to advance trials, scale manufacturing, or absorb setbacks without new financing, raising execution risk.
Large And Persistent Operating LossesDeep negative margins reflect a cost base far above revenue and show the business is not yet on a sustainable profit path. Without material, durable revenue growth or cost restructuring, losses will continue to erode capital and limit reinvestment over the medium term.
Erosion Of Shareholder Equity And AssetsMaterial declines in equity/assets reduce the balance sheet buffer available for clinical development and manufacturing scale‑up. This erosion increases vulnerability to funding shocks and could raise cost of capital, impairing long‑term program execution and partnership leverage.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.01 and its highest was AU$0.43 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$2.92M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 40 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 243,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.054%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―